

DETAILED ACTION

1. The amendment filed on 9/22/08 is acknowledged and entered.

Status of Claims

2. Claims 1-82, 87-90, 93-96, 112-115, and 118-121 have been canceled.
Claims 83-86, 91-92, 97-111, 116-117 and 122-132 are pending.

Claim Rejections under 35 U.S.C. 112

3. In view of submission of complete deposit information for the deposit of the plasmid pJJ 36-J having ATTC Accession No. PTA-3719 and plasmid pAH342 obtainable from *E. coli* BL21 (pAH342) assigned ATCC accession number 98538, the rejection of claims 86 and 99 under 35 U.S.C. 112, first paragraph is withdrawn.

Terminal Disclaimer

4. The terminal disclaimer filed on 9/22/08 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of Patent Number: 7,459,524 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Information Disclosure Statement

5. Information Disclosure Statements 9/22/08 and 9/23/08 are acknowledged, Reviewed and a signed copy of each is attached to this action.

Examiner's amendment

6. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37

CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Elizabeth Haanes and Carla Kim on 12/18/08. The application has been amended as follows:

IN THE SPECIFICATION:

Please add the following sentence before line 1, page 1

This application is a continuation of 08/942,596, filed 10/02/1997, U.S. Patent Number: 7,459,524.

Claim. 83. (Currently amended) A pharmaceutical composition comprising : ~~an isolated polypeptide comprising an amino acid sequence at least 95% identical to amino acids 29-533 of SEQ ID NO: 2~~ an isolated and substantially purified polypeptide comprising the amino acid sequence at least 95% identical to the amino acid sequence set forth as amino acids 29-533 of SEQ ID NO: 2 , and a pharmaceutically acceptable carrier; wherein said composition, when administered to female mice, eliminates or reduces the level of *C. trachomatis* in the lower genital tract following intravaginal challenge.

Claim 84. (Currently amended) The composition of claim 83, wherein said amino acid sequence comprises the amino acids 29-533 of SEQ ID NO: 2.

Claim 85. (Currently amended) The composition of claim 84, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotides 466 to 1980 of SEQ ID NO: 1.

Claim 91. (Currently amended) The composition of claim 83, wherein said amino acid sequence comprises the amino acids 29-1012 of SEQ ID NO: 2.

Claim 92. . (Currently amended) The composition of claim 91, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotides 466-3417 of SEQ ID NO: 1.

Claim 98. ((Currently amended) The composition of claim 92, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotide acid sequence SEQ ID NO: 1.

Claim 108. (Currently amended) A pharmaceutical composition comprising:
~~an isolated polypeptide comprising an amino acid sequence at least 95% identical to amino acids 29-533 of SEQ ID NO: 2~~ an isolated and substantially purified polypeptide comprising the amino acid sequence at least 95% identical to the amino acid sequence set forth as amino acids 29-533 of SEQ ID NO: 2 , and a pharmaceutically acceptable carrier; wherein said polypeptide when administered to a subject induces a cellular immune response or a humoral immune response that recognizes the polypeptide of SEQ ID NO: 2.

Claim 109. (Currently amended) The composition of claim 108, wherein said amino acid sequence comprises the amino acids 29-533 of SEQ ID NO: 2.

Claim 110. (Currently amended) The composition of claim 109, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotides 466 to 1980 of SEQ ID NO: 1.

Claim 116. (Currently amended) The composition of claim 108, wherein said amino acid sequence comprises the amino acids 29-1012 of SEQ ID NO: 2.

Claim 117. (Currently amended) The composition of claim 116, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotides 466-3417 of SEQ IDNO: 1.

Claim 123. (Currently amended) The composition of claim 122, wherein said amino acid sequence is encoded by a polynucleotide comprising the nucleotide sequence SEQ ID NO: 1.

Reasons for allowance

7. The instant claims define a novel pharmaceutical composition that comprises an isolated *Chlamydia trachomatis* serovar L2 polypeptide of SEQ ID NO: 2 and *Chlamydia trachomatis* serovars B and F, said serovars B and F are 95% identical to serovar L2 outer membrane protein, SEQ ID NO: 2 from amino acids 29-1012. The prior art does not anticipate or obviate the product of the instantly claimed invention.

Conclusion

8. Claims 83-86, 91-92, 97-111, 116-117 and 122-132 are allowed and have been renumbered as 1-34 respectively.

9. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform to the notice published in the Official Gazette, 1096 OG 30, November 156, 1989. The Right Fax number is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PMR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PMR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PMR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571) 272-0956.

Respectfully,
/Padma V Baskar/
Examiner, Art Unit 1645

/Robert B Mondesi/
Supervisory Patent Examiner, Art Unit 1645